Market closedADR
Ascendis Pharma/$ASND
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ascendis Pharma
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
Ticker
$ASND
Sector
Trading on
Industry
Biotechnology
Headquarters
Hellerup, Denmark
Employees
1,017
Website
Ascendis Pharma Metrics
BasicAdvanced
$9.9B
-
-$7.43
0.64
-
Price and volume
Market cap
$9.9B
Beta
0.64
52-week high
$169.37
52-week low
$111.09
Average daily volume
490K
Financial strength
Current ratio
1.169
Quick ratio
0.812
Long term debt to equity
-345.373
Total debt to equity
-810.376
Interest coverage (TTM)
-4.26%
Management effectiveness
Return on assets (TTM)
-17.38%
Return on equity (TTM)
300.78%
Valuation
Price to revenue (TTM)
23.105
Price to book
-93.44
Price to tangible book (TTM)
-90.01
Price to free cash flow (TTM)
-27.312
Growth
Revenue change (TTM)
36.34%
Earnings per share change (TTM)
-23.65%
3-year revenue growth (CAGR)
260.25%
3-year earnings per share growth (CAGR)
-2.30%
What the Analysts think about Ascendis Pharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Ascendis Pharma stock.
Ascendis Pharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Ascendis Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Ascendis Pharma News
AllArticlesVideos
Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory
Seeking Alpha·4 days ago
Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
GlobeNewsWire·3 weeks ago
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Ascendis Pharma stock?
Ascendis Pharma (ASND) has a market cap of $9.9B as of April 19, 2025.
What is the P/E ratio for Ascendis Pharma stock?
The price to earnings (P/E) ratio for Ascendis Pharma (ASND) stock is 0 as of April 19, 2025.
Does Ascendis Pharma stock pay dividends?
No, Ascendis Pharma (ASND) stock does not pay dividends to its shareholders as of April 19, 2025.
When is the next Ascendis Pharma dividend payment date?
Ascendis Pharma (ASND) stock does not pay dividends to its shareholders.
What is the beta indicator for Ascendis Pharma?
Ascendis Pharma (ASND) has a beta rating of 0.64. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.